Repligen Corporation (RGEN): Price and Financial Metrics
Repligen Corporation (RGEN)
Today's Latest Price: $168.75 USD
Updated Oct 19 6:55pm
Add RGEN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
RGEN Stock Summary
- RGEN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 2,912.02 -- higher than 98.56% of US-listed equities with positive expected earnings growth.
- With a price/earnings ratio of 289.79, Repligen Corp P/E ratio is greater than that of about 97.52% of stocks in our set with positive earnings.
- The price/operating cash flow metric for Repligen Corp is higher than 97.23% of stocks in our set with a positive cash flow.
- Stocks with similar financial metrics, market capitalization, and price volatility to Repligen Corp are TDOC, MLAB, PRAH, AKAM, and PAYC.
- Visit RGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.repligen.com.
RGEN Stock Price Chart Interactive Chart >
RGEN Price/Volume Stats
| Current price | $168.75 | 52-week high | $175.45 |
| Prev. close | $170.77 | 52-week low | $76.75 |
| Day low | $168.28 | Volume | 197,500 |
| Day high | $173.58 | Avg. volume | 524,583 |
| 50-day MA | $151.92 | Dividend yield | N/A |
| 200-day MA | $122.52 | Market Cap | 8.86B |
Repligen Corporation (RGEN) Company Bio
Repligen Corporation develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company was founded in 1981 and is based in Waltham, Massachusetts.
RGEN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $168.75 | $18.63 | -89% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Repligen Corp. To summarize, we found that Repligen Corp ranked in the 12th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 89%. The most interesting components of our discounted cash flow analysis for Repligen Corp ended up being:
- In the past 5.38 years, Repligen Corp has a compound free cash flow growth rate of 0.25%; that's higher than 61.67% of free cash flow generating stocks in the Healthcare sector.
- 97% of the company's capital comes from equity, which is greater than 89.47% of stocks in our cash flow based forecasting set.
- The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 10.5% of the free cash flow producing stocks we're observing.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -89% |
| 1% | -89% |
| 2% | -89% |
| 3% | -89% |
| 4% | -89% |
| 5% | -89% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as RGEN, try BLFS, ELAN, LGND, PCRX, and TEVA.
Loading social stream, please wait...